期刊文献+

High performance liquid chromatography mass spectrometric method for the simultaneous quantification of pravastatin and aspirin in human plasma:Pharmacokinetic application 被引量:5

High performance liquid chromatography mass spectrometric method for the simultaneous quantification of pravastatin and aspirin in human plasma:Pharmacokinetic application
下载PDF
导出
摘要 A rapid and sensitive liquid chromatography-tandem mass spectrometric(LC-MS/MS) assay method has been developed and fully validated for the simultaneous quantification of pravastatin and aspirin in human plasma.Furosemide was used as an internal standard.Analytes and the internal standard were extracted from human plasma by liquid-liquid extraction technique using methyl tertiary butyl ether.The reconstituted samples were chromatographed on a Zorbax SB-C_18 column by using a mixture of 5 mM ammonium acetate buffer and acetonitrile(20:80,v/v) as the mobile phase at a flow rate of 0.8 mL/min.The calibration curve obtained was linear(r≥0.99) over the concentration range of 0.50-600.29 ng/mL for pravastatin and 20.07-2012.00 ng/mL for aspirin.Method validation was performed as per FDA guidelines and the results met the acceptance criteria.A run time of 2.0 min for each sample made it possible to analyze more than 400 human plasma samples per day.The proposed method was found to be applicable to clinical studies. A rapid and sensitive liquid chromatography-tandem mass spectrometric(LC-MS/MS) assay method has been developed and fully validated for the simultaneous quantification of pravastatin and aspirin in human plasma.Furosemide was used as an internal standard.Analytes and the internal standard were extracted from human plasma by liquid-liquid extraction technique using methyl tertiary butyl ether.The reconstituted samples were chromatographed on a Zorbax SB-C_18 column by using a mixture of 5 mM ammonium acetate buffer and acetonitrile(20:80,v/v) as the mobile phase at a flow rate of 0.8 mL/min.The calibration curve obtained was linear(r≥0.99) over the concentration range of 0.50-600.29 ng/mL for pravastatin and 20.07-2012.00 ng/mL for aspirin.Method validation was performed as per FDA guidelines and the results met the acceptance criteria.A run time of 2.0 min for each sample made it possible to analyze more than 400 human plasma samples per day.The proposed method was found to be applicable to clinical studies.
出处 《Journal of Pharmaceutical Analysis》 SCIE CAS 2012年第3期206-213,共8页 药物分析学报(英文版)
关键词 PRAVASTATIN ASPIRIN Human plasma Liquid-liquid extraction LC-MS/MS PHARMACOKINETICS Pravastatin Aspirin Human plasma Liquid-liquid extraction LC-MS/MS Pharmacokinetics
  • 相关文献

参考文献20

  • 1N Dagli,M Yavuzkir,I Karaca. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid glucose metabolism and inflammation[J].Inflammation,2007.230-235.
  • 2K S Jain,M K Kathiravan,R S Somani. The biology and chemistry of hyperlipedemia[J].Bioorganic and Medicinal Chemistry Letters,2007.4674-4699.
  • 3D Wood,D G Backer,O Faergeman. Prevention of coronary heart disease in clinical practice:recommendations of the second joint task force of european and other societies on coronary prevention[J].European Heart Journal,1998.1434-1503.
  • 4T A Pearson,I Laurora,H Chu. The Lipid Treatment Assessment Project (L-TAP):a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals[J].Archives of Internal Medicine,2000.459-467.
  • 5C A Sueta,M Chowdhury,S J Boccuzzi. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease[J].American Journal of Cardiology,1999.1303-1307.
  • 6M H Davidson,P P Toth. Comparative effects of lipid-lowering therapies[J].Progress in Cardiovascular Diseases,2004.73-104.
  • 7A Corsini,S Bellosta,R Baetta. New insights into the pharmocodynamic and pharmacokinetic properties of statins[J].Journal of Veterinary Pharmacology and Therapeutics,1999.413-428.
  • 8D G Backer,E Ambrosioni,K Borch-Johnsen. European guidelines on cardiovascular disease prevention in clinical practice Third joint task force of european and other societies on cardiovascular disease prevention in clinical practice[J].European Heart Journal,2003.16011610.
  • 9A V Quion,P H Jones. Clinical pharmacokinetics of pravastatin[J].Clinical Pharmacokinetics,1994.94-103.
  • 10H Lennernas,G Fager. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors:similarities and differences[J].Clinical Pharmacokinetics,1997.403-425.

同被引文献11

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部